Genes influencing HDL metabolism: New perspectives and implications for atherosclerosis prevention

Molecular Medicine Today

Volumn 6, Issue 4, 2000, Pages 170-175

  Rader, Daniel J ^a   Maugeais, Cyrille ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN RECEPTOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR; TRIACYLGLYCEROL LIPASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG TARGETING; GENE MUTATION; GENE TRANSFER; HUMAN; LIPID COMPOSITION; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MORBIDITY; MORTALITY; REVIEW;

ANIMALS; ANTIGENS, CD36; ARTERIOSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; GENES; GLYCOPROTEINS; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS B;

EID: 0034177438     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01673-7     Document Type: Review

References (57)

1. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86:1990;379-384.
2. Gordon D.J., Rifkind B.M. High-density lipoproteins - the clinical implications of recent studies. New Engl. J. Med. 321:1989;1311-1316.
3. Badimon J.J.et al. Role of high density lipoproteins in the regression of atherosclerosis. Circulation. 86:1992;III86-III94. (Suppl. 6).
4. Tangirala R.K.et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 100:1999;1816-1822.
5. Tsukamoto K.et al. Rapid regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein E in apoE deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;2162-2170.
6. Rubins H.B.et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl. J. Med. 341:1999;410-418.
7. Reichl D., Miller N.E. Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis. 9:1989;785-797.
8. Rader D.J., Ikewaki K. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr. Opin. Lipidol. 7:1996;117-123.
9. Oram J.F., Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid Res. 37:1996;2473-2491.
10. Fielding C.J., Young S.G. The ABCs of cholesterol efflux. Nat. Genet. 22:1999;316-318.
11. Serfaty-Lacrosniere C.et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107:1994;85-98.
12. Berard A.M.et al. High plasma HDL concentration associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat. Med. 3:1997;744-749.
13. Hoeg J.M.et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11448-11453.
14. Ng D.S.et al. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J. Biol. Chem. 272:1997;15777-15781.
15. Kuivenhoven J.A.et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 38:1997;191-205.
16. Rader D.J.et al. Markedly accelerated catabolism of apolipoprotein A-II (apoA-II) and high density lipoproteins containing apoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest. 93:1994;321-330.
17. Rainwater D.L. A DNA polymorphism for LCAT is associated with altered LCAT activity and high density lipoprotein size distributions in baboons. Arterioscler. Thromb. 12:1992;682-690.
18. Lagrost L. Structure and function of the plasma phospholipid transfer protein. Curr. Opin. Lipidol. 9:1998;203-209.
19. Wolfbauer G. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim. Biophys. Acta. 1439:1999;65-76.
20. Jiang X.et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J. Clin. Invest. 98:1996;2373-2380.
21. Tu A.Y.et al. Introduction of the human PLTP transgene suppresses the atherogenic diet-induced increase in plasma phospholipid transfer activity in C57BL/6 mice. Int. J. Clin. Lab. Res. 29:1999;14-21.
22. Jiang X.C.et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103:1999;907-914.
23. Albers J.J.et al. Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strains. J. Lipid Res. 40:1999;295-301.
24. Goldberg I.J. Lipoprotein lipase and lipolysis. central roles in lipoprotein metabolism and atherogenesis J. Lipid Res. 37:1996;693-707.
25. Clee S.M.et al. Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice. modulation by cholesteryl ester transfer protein and dietary status J. Lipid Res. 38:1997;2079-2089.
26. Coleman T.et al. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270:1995;12518-12525.
27. Levak-Frank S.et al. Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma. J. Biol. Chem. 272:1997;17182-17190.
28. Levak-Frank S.et al. Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and high-density lipoprotein-cholesterol levels. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3165-3170.
29. Shimada M.et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7242-7246.
30. Babaev V.R.et al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest. 103:1999;1697-1705.
31. Blades B.et al. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 13:1993;1227-1235.
32. Hokanson J.E. Lipoprotein lipase gene variants and risk of coronary disease. a quantitative analysis of population-based studies Int. J. Clin. Lab. Res. 27:1997;24-34.
33. Wittekoek M.E. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation. 3:1998;729-735.
34. Wittrup H.H.et al. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. the Copenhagen City heart study Arterioscler. Thromb. Vasc. Biol. 19:1999;1535-1540.
35. Humphries S.E.et al. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides. the European Atherosclerosis Research Study (EARS) Arterioscler. Thromb. Vasc. Biol. 18:1998;526-534.
36. Tsutsumi K.et al. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92:1993;411-417.
37. Williams D.L.et al. Scavenger receptor BI and cholesterol trafficking. Curr. Opin. Lipidol. 10:1999;329-339.
38. Kozarsky K.F.et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
39. Rigotti A.et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key in HDL metabolism. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12610-12615.
40. Varban M.L.et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4619-4624.
41. Acton S.et al. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler. Thromb. Vasc. Biol. 19:1999;1734-1743.
42. Arai T.et al. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274:1999;2366-2371.
43. Kozarsky K.F.et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 2000;. (in press).
44. Agellon L.B. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266:1991;10796-10801.
45. Inazu A.et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. New Engl. J. Med. 323:1990;1234-1238.
46. Ikewaki K.et al. Delayed catabolism of high density lipoprotein apolipoprotein A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92:1993;1650-1658.
47. Plump A.S.et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19:1999;1105-1110.
48. Hayek T.et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96:1995;2071-2074.
49. Zhong S.et al. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:1996;2687-2688.
50. Santamarina-Fojo S.et al. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr. Opin. Lipidol. 9:1998;211-219.
51. Busch S.J.et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem. 269:1994;16376-16382.
52. Fan J.et al. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8724-8728.
53. Mezdour H.et al. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J. Biol. Chem. 272:1997;13570-13575.
54. Hegele R.et al. Hepatic lipase deficiency. clinical, biochemical, and molecular genetic characteristics Arterioscler. Thromb. 13:1993;720-728.
55. Cohen J.C.et al. Hepatic lipase. new insights from genetic and metabolic studies Curr. Opin. Lipidol. 10:1999;259-267.
56. Jaye M.et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21:1999;424-428.
57. Hirata K.et al. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J. Biol. Chem. 274:1999;14170-14175.